AV-5080 | CAS#1448435-38-8 | novel anti-influenza drug

MedKoo Cat#: 145277 | Name: AV-5080

Description:

WARNING: This product is for research use only, not for human or veterinary use.

AV5080 is a promising novel oral drug candidate for the treatment of influenza, including oseltamivir-resistant types. AV5080 is a promising orally-dosed NAI that exhibited similar or superior in vitro efficacy against viruses with reduced or highly reduced inhibition phenotypes with respect to currently approved NAIs.

Chemical Structure

AV-5080

CAS#1448435-38-8

Theoretical Analysis

MedKoo Cat#: 145277

Name: AV-5080

CAS#: 1448435-38-8

Chemical Formula: C15H25FN4O4

Exact Mass: 344.1860

Molecular Weight: 344.39

Elemental Analysis: C, 52.31; H, 7.32; F, 5.52; N, 16.27; O, 18.58

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

AV-5080; AV5080; AV 5080;

IUPAC/Chemical Name

(3R,4R,5S)-4-(2-fluoroacetamido)-5-guanidino-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylic acid

InChi Key

GPJMJWZFIQXUME-DMDPSCGWSA-N

InChi Code

1S/C15H25FN4O4/c1-3-9(4-2)24-11-6-8(14(22)23)5-10(19-15(17)18)13(11)20-12(21)7-16/h6,9-11,13H,3-5,7H2,1-2H3,(H,20,21)(H,22,23)(H4,17,18,19)/t10-,11+,13+/m0/s1

SMILES Code

CCC(CC)O[C@@H]1C=C(C[C@H](NC(N)=N)[C@H]1NC(=O)CF)C(O)=O

Appearance

To be determined

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 344.39 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Ivashchenko AA, Jones JC, Shkil DO, Ivanenkov YA, Pascua PNQ, Penaflor MK, Karapetian RN, Govorkova EA, Ivachtchenko AV. Resistance profiles for the investigational neuraminidase inhibitor AV5080 in influenza A and B viruses. Antiviral Res. 2023 Sep;217:105701. doi: 10.1016/j.antiviral.2023.105701. Epub 2023 Aug 9. PMID: 37567255; PMCID: PMC10528385. 2: Ivachtchenko AV, Ivanenkov YA, Mitkin OD, Yamanushkin PM, Bichko VV, Shevkun NA, Karapetian RN, Leneva IA, Borisova OV, Veselov MS. Novel oral anti-influenza drug candidate AV5080. J Antimicrob Chemother. 2014 Jul;69(7):1892-902. doi: 10.1093/jac/dku074. Epub 2014 Apr 11. PMID: 24729605. 3: Nguyen HT, Chesnokov A, De La Cruz J, Pascua PNQ, Mishin VP, Jang Y, Jones J, Di H, Ivashchenko AA, Killian ML, Torchetti MK, Lantz K, Wentworth DE, Davis CT, Ivachtchenko AV, Gubareva LV. Antiviral susceptibility of clade 2.3.4.4b highly pathogenic avian influenza A(H5N1) viruses isolated from birds and mammals in the United States, 2022. Antiviral Res. 2023 Sep;217:105679. doi: 10.1016/j.antiviral.2023.105679. Epub 2023 Jul 24. PMID: 37494978; PMCID: PMC10508830.